iBio, Inc. (NYSE:IBIO) has a beta value of -6.02 and has seen 41,030,243 shares traded in the recent trading session. The company, currently valued at $297.11 Million, closed the recent trade at $2.49 per share which meant it gained $0.33 on the day or 15.35% during that session. The IBIO stock price is -36.55% off its 52-week high price of $3.4 and 97.99% above the 52-week low of $0.05. If we look at the company’s 10-day average daily trading volume, we find that it stood at 38.18 Million shares traded. The 3-month trading volume is 13.86 Million shares.
The consensus among analysts is that iBio, Inc. (IBIO) is a Buy stock at the moment, with a recommendation rating of 0. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 1 have rated it as a Hold, with 1 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is $0.
iBio, Inc. (NYSE:IBIO) trade information
Sporting 15.35% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Monday, Jun 29 when the IBIO stock price touched $2.70-5 or saw a rise of 5.93%. Year-to-date, iBio, Inc. shares have moved 920.08%, while the 5-day performance has seen it change 76.39%. Over the past 30 days, the shares of iBio, Inc. (NYSE:IBIO) have changed 58.75%. Short interest in the company has seen 2.14 Million shares shorted with days to cover at 0.15.
Wall Street analysts have a consensus price target for the stock at $30, which means that the shares’ value could jump 1104.82% from current levels. The projected low price target is $30 while the price target rests at a high of $30. In that case, then, we find that the current price level is +1104.82% off the targeted high while a plunge would see the stock lose 1104.82% from current levels.
iBio, Inc. (IBIO) estimates and forecasts
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -10.1% over the past 5 years. Earnings growth for 2020 is a modest +38.7% while over the next 5 years, the company’s earnings are expected to increase by 0%.